Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis

Immunotherapy treatments for cancer are becoming increasingly successful, however to further improve our understanding of the T-cell recognition involved in effective responses and to encourage moves towards the development of personalised treatments for leukaemia immunotherapy, precise antigenic targets in individual patients have been identified. Cellular arrays using peptide-MHC (pMHC) tetramers allow the simultaneous detection of different antigen specific T-cell populations naturally circulating in patients and normal donors. We have developed the pMHC array to detect CD8+ T-cell populations in leukaemia patients that recognise epitopes within viral antigens (cytomegalovirus (CMV) and influenza (Flu)) and leukaemia antigens (including Per Arnt Sim domain 1 (PASD1), MelanA, Wilms’ Tumour (WT1) and tyrosinase). We show that the pMHC array is at least as sensitive as flow cytometry and has the potential to rapidly identify more than 40 specific T-cell populations in a small sample of T-cells (0.8–1.4 x 106). Fourteen of the twenty-six acute myeloid leukaemia (AML) patients analysed had T cells that recognised tumour antigen epitopes, and eight of these recognised PASD1 epitopes. Other tumour epitopes recognised were MelanA (n = 3), tyrosinase (n = 3) and WT1126-134 (n = 1). One of the seven acute lymphocytic leukaemia (ALL) patients analysed had T cells that recognised the MUC1950-958 epitope. In the future the pMHC array may be used provide point of care T-cell analyses, predict patient response to conventional therapy and direct personalised immunotherapy for patients.

[1]  T. Schumacher,et al.  Generation of peptide–MHC class I complexes through UV-mediated ligand exchange , 2006, Nature Protocols.

[2]  J. Pollack,et al.  Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. , 2006, Blood.

[3]  T. Schumacher,et al.  In situ detection of virus- and tumor-specific T-cell immunity , 2000, Nature Medicine.

[4]  G. Mufti,et al.  An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide. , 2013, Cancer immunity.

[5]  E. Jaffee,et al.  Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Mark M Davis,et al.  Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization , 2013, Nature Biotechnology.

[7]  C. Figdor,et al.  The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. , 1999, Cancer research.

[8]  S. Burrows,et al.  Lymphokine‐activated killer (lak) cells discriminate between epstein‐barr virus (ebv)‐positive burkitt's lymphoma cells , 1990, International journal of cancer.

[9]  A. Banham,et al.  PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy , 2006, Leukemia.

[10]  P. Romero,et al.  Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. , 1997, Journal of immunology.

[11]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by Melan-A/Mart-1 immunodominant peptide analogs , 1997 .

[12]  W. Hildebrand,et al.  Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties , 2010, Cancer Immunology, Immunotherapy.

[13]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[14]  J. Shabanowitz,et al.  Mass‐spectrometric evaluation of HLA‐A*0201‐associated peptides identifies dominant naturally processed forms of CTL epitopes from MART‐1 and gp100 , 1999 .

[15]  F. Chisari,et al.  Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. , 1996, The Journal of clinical investigation.

[16]  Jonathan P Schneck,et al.  Detection of antigen‐specific T cells on p/MHC microarrays , 2007, Journal of molecular recognition : JMR.

[17]  S. Voss,et al.  Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. , 1997, Protein engineering.

[18]  K. Rezvani,et al.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. , 2007, Blood.

[19]  T. Schumacher,et al.  UV-induced ligand exchange in MHC class I protein crystals. , 2009, Journal of the American Chemical Society.

[20]  Lloyd J. Old,et al.  Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.

[21]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[22]  C. Figdor,et al.  Renal cell carcinoma–associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen‐dr molecules to CD4+ T lymphocytes , 2002, International journal of cancer.

[23]  F. Lemonnier,et al.  ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. , 2002, Blood.

[24]  B. Gückel,et al.  Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells , 2010, Cancer Immunology, Immunotherapy.

[25]  A. Kumar,et al.  Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.

[26]  G. Ogg,et al.  Anti-HLA-A2 antibody-enhancement of peptide association with HLA-A2 as detected by cytotoxic T lymphocytes , 1989, Nature.

[27]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[28]  H. Rammensee,et al.  CD8+ T-cell response against MUC1-derived peptides in gastrointestinal cancer survivors , 2005, Cancer Immunology, Immunotherapy.

[29]  K. Parker,et al.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. , 1996, Blood.

[30]  Mark M Davis,et al.  Detection and Characterizationof Cellular Immune Responses Using Peptide–MHC Microarrays , 2003, PLoS biology.

[31]  J. Goldman,et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. , 2000, Blood.

[32]  D. Price,et al.  Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. , 1999, Journal of immunology.

[33]  E. Sercarz,et al.  Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity. , 1993, Journal of immunology.

[34]  A. Banham,et al.  Cytolytic T‐cell response to the PASD1 cancer testis antigen in patients with diffuse large B‐cell lymphoma , 2009, British journal of haematology.

[35]  J. Ozols,et al.  Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Mufti,et al.  Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia. , 2005, Biochemical and Biophysical Research Communications - BBRC.

[37]  D. Rudolf.  Efficient in vitro priming of tumor- and virus-specific CD8+ T cells with calibrated artifical APCs , 2008 .

[38]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[39]  H. Rammensee,et al.  Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools. , 1997, European journal of biochemistry.

[40]  D. Egan,et al.  High-throughput T-cell epitope discovery through MHC peptide exchange. , 2009, Methods in molecular biology.

[41]  Mark M Davis,et al.  Marked Differences in Human Melanoma Antigen-Specific T Cell Responsiveness after Vaccination Using a Functional Microarray , 2005, PLoS medicine.

[42]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[43]  H. Rammensee,et al.  High frequencies of functionally impaired cytokeratin 18‐specific CD8+ T cells in healthy HLA‐A2+ donors , 2005, European journal of immunology.

[44]  Gabriel A Kwong,et al.  Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. , 2009, Journal of the American Chemical Society.

[45]  F. Lemonnier,et al.  Novel breast‐tumor‐associated MUC1‐derived peptides: Characterization in Db−/− × β2 microglobulin (β2m) null mice transgenic for a chimeric HLA‐A2.1/Db‐β2 microglobulin single chain , 2000 .

[46]  H. Rammensee,et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.

[47]  A. Vitiello,et al.  HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. , 1993, Journal of immunology.

[48]  F. Lemonnier,et al.  Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain. , 2000, International journal of cancer.

[49]  D. Mason,et al.  A very high level of crossreactivity is an essential feature of the T-cell receptor. , 1998, Immunology today.

[50]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[51]  R. Rees,et al.  HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides , 2007, Cancer Immunology, Immunotherapy.

[52]  C. Craddock,et al.  Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses , 2013, British journal of haematology.

[53]  V. Levitsky,et al.  Solvent exposed side chains of peptides bound to HLA A*1101 have similar effects on the reactivity of alloantibodies and specific TCR. , 1996, International immunology.

[54]  T. Akiyama,et al.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.

[55]  S. Gnjatic,et al.  Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules , 1995, European journal of immunology.

[56]  A. Mirzabekov,et al.  Protein microchips: use for immunoassay and enzymatic reactions. , 2000, Analytical biochemistry.

[57]  K. Mills,et al.  Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangements. , 2009, Blood.

[58]  Hans-Georg Rammensee,et al.  Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.

[59]  E. King,et al.  The immune response in HPV+ oropharyngeal cancer , 2014, Oncoimmunology.

[60]  Evan W. Newell,et al.  Simultaneous detection of many T-cell specificities using combinatorial tetramer staining , 2009, Nature Methods.

[61]  T. Schumacher,et al.  Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7 , 2008, Proceedings of the National Academy of Sciences.

[62]  Sean C. Bendall,et al.  Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. , 2012, Immunity.

[63]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[64]  S. Modrow,et al.  Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers. , 1999, Virology.

[65]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[66]  X. Jin,et al.  The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL , 1996, Journal of virology.

[67]  D. Jäger,et al.  Antigen‐specific immunotherapy and cancer vaccines , 2003, International journal of cancer.

[68]  Ton N Schumacher,et al.  Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers , 2009, Nature Methods.